Panacea Pharmaceuticals Announces Appointment of Suzanne Sensabaugh as Vice President, Regulatory Affairs

August 5, 2008 - Gaithersburg, Maryland - Panacea Pharmaceuticals, Inc. today announced the appointment of Suzanne Sensabaugh as Vice President, Regulatory Affairs. Ms. Sensabaugh will assume responsibility for formulating strategies and managing all U.S. and foreign regulatory filings for the Company's therapeutic and diagnostic products. This role is of critical importance as the Company prepares to file applications with the U.S. Food and Drug Administration for approval of its prostate and lung cancer diagnostic tests, and to begin clinical trials of its cancer and neuroprotectant therapeutic products within the next 12 months.

Read More

Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect®, Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007

December 18, 2007 - Gaithersburg, Maryland - Panacea Pharmaceuticals' lung cancer diagnostic test, LC Detectsm, has been named one of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 (click here). LC Detect® is a simple blood test to facilitate the identification of lung cancer, even among individuals with early-stage disease. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at www.panacea-labs.com. Read More

Panacea Pharmaceuticals Initiates GMP Manufacturing of Prostate Cancer Diagnostic Test Kits

December 11, 2007 - Gaithersburg, Maryland - Panacea Pharmaceuticals, Inc. has initiated manufacturing of PC Detect® kits, the Company's diagnostic test for prostate cancer, under GMP conditions. Data on the performance of the PC Detect® kit will be included in a Premarket Approval (PMA) application for this diagnostic test to be filed with the U.S. Food and Drug Administration in early 2008.

Read More

Panacea Pharmaceuticals Announces the Availability of CC Detect®, a Serum-Based Diagnostic Test for Colon Cancer

November 14, 2007 - Gaithersburg, Maryland - Panacea Pharmaceuticals, Inc. announced today that CC Detect®, the Company's serum-based colon cancer diagnostic test, is now available from Panacea Laboratories. CC Detect® is a simple blood test that should facilitate the identification of individuals with cancer of the colon and rectum when used in conjunction with standard screening methods. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at www.panacea-labs.com. Read More

Panacea Pharmaceuticals Announces the Availability of BC Detect®, a Serum-Based Diagnostic Test for Breast Cancer

O

ctober 17, 2007: Gaithersburg, Maryland — Panacea Pharmaceuticals, Inc. announced today that BC Detect®, the Company’s serum-based breast cancer diagnostic test, is now available from Panacea Laboratories. BC Detect® is a simple blood test that should facilitate the identification of recurrence among women successfully treated for breast cancer. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at www.panacea-labs.com.

Read More

Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies

September 3, 2008 - Gaithersburg, Maryland - Panacea Pharmaceuticals, Inc. today announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target. These antibodies were developed in collaboration with the Massachusetts Institute of Technology (MIT) and Panacea has exclusive, worldwide rights to this patent for development of human cancer diagnostics and therapeutics. Panacea is developing PAN-622, an all-human sequence anti-HAAH monoclonal antibody covered under this patent, as a cancer therapeutic antibody drug and anticipates the start of Phase 1 clinical trials in early 2009.

Read More

Panacea Pharmaceuticals Announces the Availability of LC Detect®, a Serum-Based Diagnostic Test for Lung Cancer

J

uly 17, 2007 - Gaithersburg, Maryland - Panacea Pharmaceuticals, Inc. announced today that LC Detect®, the Company's serum-based lung cancer diagnostic test, is now available from Panacea Laboratories. LC Detect® is a simple blood test which should facilitate the identification of lung cancer, even among individuals with early-stage disease. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at www.panacea-labs.com.

Read More

Panacea Pharmaceuticals Announces the Availability of PC Detect® for Prostate Cancer Screening

May 31, 2007- Gaithersburg, Maryland - Panacea Pharmaceuticals, Inc. announced today that PC Detect®, the Company's prostate cancer screening test, is now available from Panacea Laboratories. PC Detect® is a simple blood test, which is recommended as an adjunct to the prostate specific antigen (PSA) test and the digital rectal examination (DRE), the currently recommended prostate cancer screening methods. The addition of PC Detect® to the current screening methods is expected to improve the diagnosis of prostate cancer among men with prostate specific antigen (PSA) values below the currently recommended level for prostate biopsy. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Read More

Panacea Pharmaceuticals Initiates Pivotal, Prospective Multi-Center Study to Evaluate the Diagnostic Performance of PC Detectsm for Prostate Cancer Screening

www.panacea-labs.com), a division of Panacea Pharmaceuticals, which is fully compliant with the requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The Company anticipates submission of a Pre-Market Application (PMA) to the U.S. Food and Drug Administration later in 2007 to facilitate development of a PC Detect® kit, which will be commercialized through clinical laboratories around the country.

Read More

Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs

January 10, 2007 - Gaithersburg, Maryland - Panacea Pharmaceuticals, Inc. announced the appointment of Pamela Harris, MD, as Vice President Medical and Clinical Affairs. Dr. Harris will lead the design and conduct of clinical trials for the Company's therapeutic and diagnostic products for cancer and diseases of the central nervous system, and provide information to physicians and other health care providers on these diseases, and their diagnosis and treatment.

Read More